Substantial Holder's Percentage Ownership Drops, Signaling Significant Dilution
ATHE sits 69% above its 52-week low of $2.66.
Summary
Alterity Therapeutics' ADR depositary reported a drop in its percentage ownership, implying significant dilution from new share issuance by the company.
Key Events · Financing and Capital Events · ATHE
-
Substantial Holder's Percentage Ownership Decreased
The Bank of New York Mellon Corporation's voting power in Alterity Therapeutics Limited decreased from 28.16% to 26.22%.
-
Absolute Share Count Increased for Depositary
The depositary's absolute shareholding increased from 2,735,828,317 to 2,851,674,748 ordinary shares.
-
Implied Significant Share Dilution
The increase in absolute shares held by the depositary, coupled with a decrease in its percentage ownership, indicates a substantial increase in Alterity Therapeutics' total outstanding shares, leading to significant dilution for existing shareholders.
Analysis · ATHE · Life Sciences
The Bank of New York Mellon Corporation, acting as the depositary for Alterity Therapeutics' ADR program, reported a decrease in its percentage voting power from 28.16% to 26.22%. This occurred despite an increase in the absolute number of shares held by the depositary, indicating a substantial increase in the company's total outstanding shares. This implied dilution can significantly impact per-share metrics and investor sentiment, suggesting the company has raised capital through new share issuance.
At the time of this filing, ATHE was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.7M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.